Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

VIA expands pipeline with Roche's cardio, metabolic programs

Executive Summary

Roche has licensed VIA Pharmaceuticals (vascular inflammation and metabolic diseases) exclusive worldwide rights to its oral thyroid hormone receptor (THR) beta agonist and diacylglycerol acyl transferase 1 (DGAT1) inhibitor programs, which are both at the preclinical stage. NOTE: The oral thyroid hormone receptor (THR) beta agonist is known as lab code MGL3196.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies